PTJ
KBIO

Paul Tudor Jones’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Paul Tudor Jones’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,625
Closed -$565K – 1467
2013
Q3 		$565K Buy
+15,625
New +$712K 0.02% 289

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
LBH
Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Paul Tudor Jones's KBIO Position: Q4 2013 in Review

Paul Tudor Jones sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2013, closing a stake of 15,625 shares — an estimated $565K sold.

Paul Tudor Jones first reported a position in KBIO in Q3 2013 and held it in 1 quarter. The position peaked at $565K in Q3 2013. 46 funds tracked by Wall St. Rank hold KBIO as of Q4 2013.

  • Paul Tudor Jones reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2013 after selling out during the quarter.
  • Paul Tudor Jones sold 15,625 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2013, an estimated $565K.
  • Paul Tudor Jones first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2013 and held it in 1 quarter.
  • Paul Tudor Jones's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $565K in Q3 2013.
  • 46 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2013.

Based on Tudor Investment Corp's 13F filing for Q4 2013, filed 14 Feb 2014.